Shipped USA Domestic
Dragon Pharma, Europe
MK 677
Oral · 25 mg/tab · 100 tabs
$160.00
Compound ID
Ibutamoren
Dosage
10–25 mg/day
Concentration
25 mg/tablet
Form
100 Tablets × 25 mg
Half-life
Approximately 24 hours
Properties
Shipping
Not available in this combination
Product overview
Dragon Pharma Ibutamoren MK-677 25mg — Clinical-Grade Growth Hormone Secretagogue for Systemic Recovery, Deep Sleep & Sustainable Anabolism
Dragon Pharma Ibutamoren MK-677 25mg represents a paradigm shift in non-invasive growth hormone optimization, offering athletes and physique competitors a powerful yet fundamentally different pathway to enhanced recovery, body composition, and tissue regeneration. Unlike selective androgen receptor modulators or anabolic steroids that operate through direct hormonal receptor activation, MK-677 functions as a potent, orally bioavailable growth hormone secretagogue that mimics the endogenous hunger hormone ghrelin. By stimulating pulsatile release of natural growth hormone and downstream insulin-like growth factor 1 from the pituitary gland, this compound creates a systemic anabolic environment that enhances deep-wave sleep, accelerates connective tissue repair, supports lean mass accretion, and optimizes lipolytic metabolism—all without suppressing endogenous testosterone or stressing hepatic function. Dragon Pharma's precisely manufactured 25mg tablets, verified for potency and purity through independent analytical testing, provide a pharmaceutical-grade tool for individuals seeking to unlock their body's intrinsic regenerative capacity through a clean, sustainable mechanism.
What is Dragon Pharma MK-677?
MK-677, scientifically designated as Ibutamoren, is a non-peptidic, orally active growth hormone secretagogue that functions as a high-affinity agonist at the ghrelin receptor (GHS-R1a) within the hypothalamus and pituitary gland. Unlike exogenous human growth hormone injections that deliver a constant, non-physiological hormone concentration, Ibutamoren stimulates the body's own endogenous pulsatile secretion pattern, elevating both growth hormone and IGF-1 levels in a manner that preserves natural feedback loops. Originally developed to address growth hormone deficiency, muscle wasting, and age-related catabolism, MK-677 has transcended its clinical origins to become a cornerstone of advanced recovery protocols. Its mechanism is entirely non-hormonal in the traditional androgenic sense—it does not interact with androgen, estrogen, or progesterone receptors, rendering it completely non-suppressive and suitable for extended-duration use by both male and female athletes. Dragon Pharma's 25mg oral formulation delivers this unique pharmacological profile with verified dosing consistency and manufacturing precision.
Key Benefits / Effects
- Restorative Sleep Architecture Enhancement: MK-677 significantly amplifies slow-wave sleep duration and quality, the most anabolically restorative sleep phase, resulting in faster cognitive recovery, reduced sleep latency, and profoundly refreshed waking states.
- Accelerated Musculoskeletal Regeneration: Elevated IGF-1 signaling stimulates collagen synthesis, tendon remodeling, ligament strengthening, and bone mineral density improvement, dramatically shortening recovery intervals between high-volume training sessions.
- Sustainable Lean Tissue Accretion: The systemic anabolic environment fostered by increased GH and IGF-1 promotes steady, high-quality muscle protein synthesis without the rapid fluid shifts or estrogenic complications associated with traditional bulking agents.
- Enhanced Lipolytic Metabolism: Growth hormone's well-documented fat-mobilizing properties shift substrate utilization toward stored triglycerides, particularly during nocturnal fasting windows, supporting gradual yet consistent adipose reduction from stubborn deposit areas.
- Appetite Stimulation for Mass Phases: Ghrelin-mimetic activity produces a substantial increase in hunger signaling, proving invaluable for hardgainers and athletes in aggressive caloric surplus who struggle to meet elevated macronutrient targets.
- Dermal and Connective Tissue Vitality: Increased systemic collagen production improves skin thickness and elasticity, accelerates nail growth, and supports hair follicle health, contributing to an overall rejuvenated aesthetic appearance.
How Dragon Pharma MK-677 Works
The compound's primary mechanism centers on agonism at the growth hormone secretagogue receptor (GHS-R1a), a G-protein-coupled receptor densely expressed in the arcuate nucleus of the hypothalamus and the anterior pituitary. Upon binding, Ibutamoren triggers a signaling cascade that amplifies the amplitude and frequency of growth hormone-releasing hormone (GHRH)-mediated pulses from somatotroph cells. This endogenous GH surge subsequently stimulates hepatic IGF-1 production, which serves as the primary mediator of growth hormone's anabolic and restorative effects at the tissue level. In skeletal muscle, IGF-1 activates the PI3K/Akt/mTOR pathway, upregulating protein synthesis and satellite cell recruitment. In connective tissue, it enhances fibroblast activity and type I collagen deposition. In adipocytes, growth hormone stimulates hormone-sensitive lipase, increasing free fatty acid mobilization. Because MK-677 elevates GH through physiological secretory patterns rather than direct hormone replacement, it avoids the receptor desensitization and feedback suppression commonly associated with exogenous GH administration, while still delivering measurable improvements in recovery, body composition, and systemic well-being.
Usage Information
Dragon Pharma MK-677 is supplied as 25mg oral tablets with a pharmacokinetic half-life of approximately 24 hours, supporting convenient once-daily administration. Beginner users typically initiate at 10–15mg daily to assess individual tolerance to ghrelin-mediated appetite stimulation and transient fluid retention. Intermediate and advanced practitioners generally employ 20–25mg daily, representing the optimal range for maximizing endogenous GH output and experiencing the full spectrum of recovery and metabolic benefits. Some experienced users may explore 25–30mg daily, though side effect intensity often increases disproportionately to additional hormonal gains beyond the 25mg threshold. Administration 30–60 minutes before bedtime is the preferred timing protocol, as it capitalizes on the body's natural nocturnal GH pulse, enhances sleep architecture, and mitigates potential daytime lethargy or hunger disturbances. Unlike SARMs or steroids, MK-677 requires no cycling off for hormonal recovery; protocols frequently extend from 12 weeks to 6 months or longer, with benefits accumulating progressively over time. No post-cycle therapy is necessary, and the compound integrates seamlessly into virtually any training, cutting, bulking, or rehabilitation protocol.
Quality & Manufacturing
Dragon Pharma maintains rigorous pharmaceutical-grade manufacturing standards, with each MK-677 batch subjected to independent third-party laboratory analysis to verify identity, purity, and potency. Recent analytical testing confirmed potency very close to the labeled 25mg claim, ensuring users receive the full intended pharmacological payload with every administration. This dosing fidelity is particularly critical for growth hormone secretagogues, where consistent daily plasma levels are necessary to achieve stable, elevated GH and IGF-1 concentrations over time. Erratic dosing from underfilled or counterfeit products would produce suboptimal pulsatile patterns and diminished systemic benefits. Dragon Pharma's commitment to analytical transparency and batch consistency eliminates this uncertainty, providing athletes with a reliable platform for long-term recovery optimization and metabolic enhancement.
Possible Side Effects / Safety Information
- Intensified Appetite Signaling: Ghrelin-mimetic activity frequently produces substantial hunger increases that, while beneficial for bulking, may require disciplined dietary management during caloric restriction phases.
- Transient Extracellular Fluid Retention: Temporary water accumulation in the hands, feet, and facial tissues may occur during the initial weeks of use; this is distinct from estrogenic edema and typically resolves as the body adapts, with sodium moderation offering symptomatic relief.
- Adaptation-Phase Lethargy: Some users experience transient tiredness or cognitive fog during the first 1–2 weeks as the neuroendocrine system adjusts to elevated GH pulsatility; nocturnal dosing largely mitigates this concern.
- Peripheral Neuropathy Symptoms: Mild tingling or numbness in the extremities may result from fluid retention exerting pressure on peripheral nerves; these sensations generally subside as water balance stabilizes.
- Insulin Sensitivity Modulation: Elevated GH can induce temporary insulin resistance and modest blood glucose elevation; monitoring carbohydrate intake and incorporating glucose disposal agents such as Berberine or cinnamon extract is prudent for metabolic management.
- Absence of Hormonal Suppression: MK-677 does not interact with the hypothalamic-pituitary-gonadal axis, producing zero testosterone suppression and eliminating the need for post-cycle therapy or endocrine recovery protocols.
- Absence of Hepatotoxicity: The compound is not C17-alpha alkylated and does not stress hepatic enzyme systems, supporting safe long-term administration without liver support supplementation.
Why Choose Dragon Pharma MK-677?
The research peptide and secretagogue marketplace is notoriously inconsistent, with MK-677 frequently underdosed, degraded, or contaminated with unrelated compounds that compromise both efficacy and safety. Dragon Pharma's verified analytical testing and transparent potency disclosure ensure that each 25mg tablet delivers the precise ghrelin-mimetic activity required for measurable, cumulative growth hormone elevation. For athletes seeking a non-suppressive, organ-friendly compound that enhances sleep architecture, accelerates injury recovery, supports sustainable lean mass development, and optimizes metabolic health over extended timelines, this formulation provides a uniquely clean and reliable platform. The ability to run MK-677 for months without hormonal disruption or liver stress makes it an ideal foundational compound for virtually any performance or physique goal.
Product FAQ
Questions, answered
While exogenous HGH delivers a constant, supraphysiological hormone level that can desensitize receptors and suppress natural production, MK-677 stimulates the body's own endogenous pulsatile GH secretion pattern. This preserves natural feedback mechanisms, avoids receptor downregulation, and produces a more physiologically harmonious elevation in both GH and IGF-1. Additionally, oral administration eliminates injection requirements, storage complexities, and the high cost associated with pharmaceutical-grade HGH.
No. MK-677 is entirely non-hormonal and does not interact with the hypothalamic-pituitary-gonadal axis. It elevates growth hormone and IGF-1 through ghrelin receptor agonism in the pituitary, leaving testosterone, luteinizing hormone, and follicle-stimulating hormone completely unaffected. This makes it uniquely suitable for use during PCT, between steroid cycles, or alongside SARMs without compounding suppressive burden.
Unlike SARMs or steroids that produce rapid acute changes, MK-677 operates through cumulative, systemic adaptation. While sleep quality and recovery improvements often manifest within the first 1–2 weeks, measurable changes in body composition, skin quality, and connective tissue strength typically consolidate over 8–12 weeks. Extended protocols of 4–6 months yield the most pronounced benefits, as GH and IGF-1 levels stabilize and tissue remodeling progresses.
Evening administration 30–60 minutes before bedtime is the preferred protocol. This timing aligns with the body's natural nocturnal GH pulse, amplifies slow-wave sleep architecture, and allows potential daytime side effects such as lethargy or intense hunger to occur during sleep rather than waking hours. The 24-hour half-life ensures stable plasma concentrations regardless of minor timing variations.
Absolutely. MK-677 serves as an exceptional foundational compound in virtually any stack. During bulking phases, it pairs with LGD-4033 to enhance appetite and support the recovery demands of intense hypertrophy training. During cutting, it combines with Ostarine or Cardarine to preserve lean mass and maintain sleep quality despite caloric restriction. In PCT or bridge phases, it helps retain cycle gains while natural testosterone recovers. Its non-suppressive nature makes it universally compatible.
The ghrelin-mimetic hunger surge can be intense, particularly at higher doses. Strategic management includes consuming high-volume, low-calorie foods such as leafy greens and fibrous vegetables, maintaining adequate hydration, spacing protein intake evenly throughout the day, and considering appetite-modulating supplements like psyllium husk or glucomannan. Some users temporarily reduce to 10–15mg daily during aggressive deficits to balance benefits against dietary adherence.
Transient extracellular fluid retention is common during the initial 2–4 weeks of use, particularly in the extremities and face. This is not estrogen-mediated subcutaneous bloating but rather GH-induced sodium and water handling shifts. The effect typically subsides as the body adapts, and reducing dietary sodium, increasing potassium intake, and maintaining hydration can accelerate normalization. Long-term users often report a leaner, tighter appearance as lipolytic effects dominate.
Given its non-hepatotoxic, non-suppressive profile, MK-677 is among the safer compounds for extended administration. However, long-term users should monitor fasting blood glucose and HbA1c due to potential insulin resistance, maintain cardiovascular activity to support metabolic health, and periodically assess lipid panels. The absence of organ stress or hormonal disruption supports protocols lasting 6 months or longer under responsible health monitoring.
Yes. Because MK-677 does not interact with androgen receptors or alter sex hormone production, it carries zero risk of virilization, voice deepening, menstrual disruption, or clitoral enlargement. Women can utilize the same 10–25mg dosing range as men and experience comparable benefits in sleep quality, recovery, fat loss, and connective tissue health without any androgenic complications.
Key panels include fasting blood glucose, HbA1c, fasting insulin, lipid profiles (total cholesterol, HDL, LDL, triglycerides), and IGF-1 levels. Baseline testing before initiation, follow-up assessment at week 8–12, and periodic monitoring every 3–4 months during extended use provide comprehensive metabolic oversight. These markers help guide dose adjustments and identify any need for glucose disposal support.
